Rigel Pharmaceuticals (RIGL) Set to Release Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is anticipated to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Rigel Pharmaceuticals to announce earnings of $0.9210 per share and revenue of $80.10 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.79. The firm had revenue of $78.70 million for the quarter, compared to the consensus estimate of $55.27 million. Rigel Pharmaceuticals had a net margin of 116.30% and a return on equity of 22.95%. On average, analysts expect Rigel Pharmaceuticals to post $2.98 EPS for the current fiscal year and $4.32 EPS for the next fiscal year.

Rigel Pharmaceuticals Stock Up 3.7%

Rigel Pharmaceuticals stock opened at $49.91 on Tuesday. Rigel Pharmaceuticals has a 52-week low of $24.95 and a 52-week high of $52.24. The firm has a market capitalization of $923.33 million, a price-to-earnings ratio of 3.06 and a beta of 1.19. The firm has a 50-day moving average price of $47.18 and a two-hundred day moving average price of $37.08.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on RIGL shares. Citigroup reissued a “buy” rating on shares of Rigel Pharmaceuticals in a report on Thursday, August 6th. Zacks Research lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. HC Wainwright reissued a “buy” rating and issued a $85.00 price target on shares of Rigel Pharmaceuticals in a research note on Monday, October 19th. Piper Sandler restated a “neutral” rating and set a $49.00 price target (up from $40.00) on shares of Rigel Pharmaceuticals in a report on Monday, August 17th. Finally, Weiss Ratings upgraded Rigel Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rigel Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $59.00.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel’s primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.